|0.8044||-0.0259||-3.12%||Vol 125.79K||1Y Perf -38.95%|
|Sep 22nd, 2023 16:00 DELAYED|
|- -||0.00 -0.55%|
|Target Price||11.00||Analyst Rating||Moderate Buy 2.33|
|Potential %||1.27K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||★ 38.80|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Price Range Ratio 52W %||6.31||Earnings Rating||Strong Buy|
|Market Cap||19.68M||Earnings Date||13th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||13th Nov 2023|
|Estimated EPS Next Report||-0.13|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||221.55K|
|Avg. Monthly Volume||6.55M|
|Avg. Quarterly Volume||2.32M|
Acer Therapeutics Inc. (NASDAQ: ACER) stock closed at 0.8044 per share at the end of the most recent trading day (a -3.12% change compared to the prior day closing price) with a volume of 125.79K shares and market capitalization of 19.68M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Acer Therapeutics Inc. CEO is Chris Schelling.
The one-year performance of Acer Therapeutics Inc. stock is -38.95%, while year-to-date (YTD) performance is -67.95%. ACER stock has a five-year performance of -97.4%. Its 52-week range is between 0.5515 and 4.56, which gives ACER stock a 52-week price range ratio of 6.31%
Acer Therapeutics Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 16.46, a price-to-sale (PS) ratio of 201.62, a price to cashflow ratio of 31.40, a PEG ratio of -, a ROA of -99.18%, a ROC of -147.90% and a ROE of 410.14%. The company’s profit margin is -%, its EBITDA margin is -6 582.90%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Acer Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Acer Therapeutics Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Acer Therapeutics Inc. is Moderate Buy (2.33), with a target price of $11, which is +1 267.48% compared to the current price. The earnings rating for Acer Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Acer Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Acer Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.98, ATR14 : 0.10, CCI20 : -22.47, Chaikin Money Flow : -0.12, MACD : 0.01, Money Flow Index : 22.58, ROC : -7.47, RSI : 47.81, STOCH (14,3) : 1.63, STOCH RSI : 0.00, UO : 46.88, Williams %R : -98.37), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Acer Therapeutics Inc. in the last 12-months were: Chris Schelling (Buy at a value of $1 000 000), Stephen Aselage (Buy at a value of $500 000)
Thu, 31 Aug 2023 11:37 GMT Zevra Therapeutics to acquire Acer Therapeutics in potential $91M transaction- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.